Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma

INTRODUCTION: Ciltacabtagene autoleucel (cilta-cel), is a B-cell maturation antigen-directed, genetically modified autologous chimeric antigen receptor T-cell (CAR-T) immunotherapy. It is indicated for treatment for adult patients with relapsed or refractory multiple myeloma (RRMM) after four or mor...

Descripción completa

Detalles Bibliográficos
Autores principales: Jagannath, Sundar, Joseph, Nedra, Crivera, Concetta, Kharat, Akshay, Jackson, Carolyn C., Valluri, Satish, Cost, Patricia, Phelps, Hilary, Slowik, Rafal, Klein, Timothy, Smolen, Lee, Yu, Xueting, Cohen, Adam D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260711/
https://www.ncbi.nlm.nih.gov/pubmed/37014590
http://dx.doi.org/10.1007/s40487-023-00228-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260711/
https://www.ncbi.nlm.nih.gov/pubmed/37014590
http://dx.doi.org/10.1007/s40487-023-00228-5

Ejemplares similares